A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Ad

Brief description of study

If you have been diagnosed with advanced malignancies, an advanced form of cancer, you may be qualified to participate in this Phase I study evaluating the drug REGN3767 alone or in combination with REGN2810. The goal of this study is to determine if the experimental drug REGN3767 is safe and tolerable alone or in combination with REGN2810 in treating patients who have advanced malignancies.

Clinical Study Identifier: s17-00257
ClinicalTrials.gov Identifier: NCT03005782

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.